Vertex touts promising launch for non-opioid pain drug Journavx
Vertex said it's gathering momentum with its new product launches, building out new franchises with its sickle cell therapy Casgevy, another cystic fibrosis drug in Alyftrek, and the non-opioid pain...
View ArticleSingapore cardio gene therapy biotech collects $45M as it plots Europe expansion
A Singapore-based startup raised a $45 million Series B to start testing a gene therapy in humans next year for a genetic heart muscle disorder, signaling that the AAV-based gene therapy field still...
View ArticleAldeyra plots third FDA filing for dry eye disease drug after latest Phase 3...
Aldeyra Therapeutics isn’t giving up on its drug candidate for dry eye disease despite a challenging path so far. The company is preparing to file reproxalap with the FDA for the third time after a ...
View ArticleDegradation startup raises $39M for pivot to PROTACs and clinical entry
PAQ Therapeutics has taken a new direction. The startup shifted its protein degradation approach to the more common PROTAC lane, pivoted to cancer, hired a chief medical officer from Frontier...
View ArticleLilly to pay up to $415M in ALS deal; Actuate’s mid-stage pancreatic cancer data
Plus, news about Atara Biotherapeutics, Immutep, bluebird bio, OSE Immunotherapeutics, Mersana Therapeutics, Innovent, Biomea Fusion and Trailhead Biosystems: Eli Lilly does another ALS deal: The...
View ArticleVertex pauses study of mRNA therapy for cystic fibrosis
Vertex paused an early-stage trial of its inhaled treatment for cystic fibrosis that came from a partnership with Moderna. The biotech said Monday in its first-quarter press release that it's...
View ArticleAnti-aging biotech NewLimit raises $130M Series B round
NewLimit, an anti-aging biotech startup backed by Coinbase CEO Brian Armstrong, has raised a $130 million Series B round to get its lead drug candidates closer to human testing. The South San...
View ArticleControversial doctor Vinay Prasad named CBER director at FDA
FDA Commissioner Marty Makary named Vinay Prasad as the next director of the Center for Biologics Evaluation and Research, putting a strident critic of the agency in charge of one of its most important...
View ArticleEurope pledges €500M to attract global science talent
The European Union is committing €500 million ($556 million) over the next two years to make Europe a “magnet” for researchers from around the world. The funding was announced Monday by European...
View ArticleTrump, FDA zero in on foreign factories to give domestic sites an edge
With several large pharma companies promising billions of dollars to reshore manufacturing to the US, President Donald Trump and the FDA have started on plans that would give current and future...
View ArticlePlans to match US drug prices to those overseas gain steam in Washington
House and Senate lawmakers from both parties are working with the Trump administration on proposals that would use drug prices paid by other developed countries as a reference for the US, an idea that...
View ArticleSEC expected to drop investigation of Illumina's $8B Grail deal
The SEC is expected to drop an investigation into Illumina's $8 billion acquisition of cancer test developer Grail, Endpoints News has learned. In 2023, Illumina disclosed in a regulatory filing that...
View ArticleStates sue US over plan for reorganization of federal health agencies
Attorneys general from 19 states and Washington, DC have filed a lawsuit against the federal government alleging that its plan for a broad restructuring of health agencies is “an unlawful effort to...
View ArticleSarepta’s stock plummets after Prasad appointment, low Elevidys sales
Sarepta Therapeutics had a bad day in Washington. And then a worse one on Wall Street. On Tuesday, the company's stock fell 27% following the news that Vinay Prasad would be the new head of ...
View ArticleMarea heads to Phase 2b after updated biomarker data show CV drug’s promise
Marea Therapeutics said on Wednesday that its lipid-lowering antibody cut both remnant cholesterol levels and remnant triglycerides — both indicators for cardiovascular disease in at-risk patients. The...
View ArticleVinay Prasad's FDA appointment sends biotech stocks lower
How did biopharma stocks react to Vinay Prasad’s appointment as director of one of the FDA's top jobs? Not well. Prasad, a hematologist-oncologist by training who gained prominence for criticizing the...
View ArticleNovo Nordisk Q1 earnings: Growth forecast trimmed as GLP-1 compounder ban yet...
Novo Nordisk said on Wednesday that compounding pharmacies’ production of its GLP-1 medicine semaglutide had reduced its market penetration more dramatically than it had expected — causing it to cut...
View ArticleCRISPR Therapeutics' gene editing therapy reduces bad cholesterol and...
CRISPR Therapeutics has revealed promising but early data from its first clinical study of a gene editing therapy to lower the risk of heart disease, setting the stage for competition with other...
View ArticleEndpoints livestream: What Vinay Prasad means for CBER and FDA
Today on our livestream, we talked about the surprise news that Vinay Prasad will replace Peter Marks at the FDA, and lead the Center for Biologics Evaluation and Research. You can ...
View ArticleTheriva’s oncolytic virus succeeds in pancreatic cancer study, but stock falls
Theriva Biologics' experimental oncolytic virus treatment and chemotherapy helped patients in a mid-stage study stay alive longer than chemotherapy alone. The company said Wednesday that the Phase 2b...
View Article